Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CCL3 in the bone marrow microenvironment causes bone loss and bone marrow adiposity in aged mice
Degang Yu, Shuhong Zhang, Chao Ma, Sen Huang, Long Xu, Jun Liang, Huiwu Li, Qiming Fan, Guangwang Liu, Zanjing Zhai
Degang Yu, Shuhong Zhang, Chao Ma, Sen Huang, Long Xu, Jun Liang, Huiwu Li, Qiming Fan, Guangwang Liu, Zanjing Zhai
View: Text | PDF
Research Article Aging Bone biology

CCL3 in the bone marrow microenvironment causes bone loss and bone marrow adiposity in aged mice

  • Text
  • PDF
Abstract

The central physiological role of the bone marrow renders bone marrow stromal cells (BMSCs) particularly sensitive to aging. With bone aging, BMSCs acquire a differentiation potential bias in favor of adipogenesis over osteogenesis, and the underlying molecular mechanisms remain unclear. Herein, we investigated the factors underlying age-related changes in the bone marrow and their roles in BMSCs’ differentiation. Antibody array revealed that CC chemokine ligand 3 (CCL3) accumulation occurred in the serum of naturally aged mice along with bone aging phenotypes, including bone loss, bone marrow adiposity, and imbalanced BMSC differentiation. In vivo Ccl3 deletion could rescue these phenotypes in aged mice. CCL3 improved the adipogenic differentiation potential of BMSCs, with a positive feedback loop between CCL3 and C/EBPα. CCL3 activated C/EBPα expression via STAT3, while C/EBPα activated CCL3 expression through direct promoter binding, facilitated by DNA hypomethylation. Moreover, CCL3 inhibited BMSCs’ osteogenic differentiation potential by blocking β-catenin activity mediated by ERK-activated Dickkopf-related protein 1 upregulation. Blocking CCL3 in vivo via neutralizing antibodies ameliorated trabecular bone loss and bone marrow adiposity in aged mice. This study provides insights regarding age-related bone loss and bone marrow adiposity pathogenesis and lays a foundation for the identification of new targets for senile osteoporosis treatment.

Authors

Degang Yu, Shuhong Zhang, Chao Ma, Sen Huang, Long Xu, Jun Liang, Huiwu Li, Qiming Fan, Guangwang Liu, Zanjing Zhai

×

Figure 6

CCL3 inhibits osteogenic differentiation potential of BMSCs by ERK-mediated Dkk1 upregulation.

Options: View larger image (or click on image) Download as PowerPoint
CCL3 inhibits osteogenic differentiation potential of BMSCs by ERK-media...
(A) mRNA expression of Runx2, Opn, Bsp, and Ocn when BMSCs from young mice undergo osteogenic differentiation with rCCL3 treatment (n = 10). (B) AR staining and quantification of BMSCs cultured from young mice with rCCL3 treatment. Scale bar: 20 μm. (C) mRNA expression of Runx2, Opn, Bsp, and Ocn when BMSCs from aged mice undergo osteogenic differentiation with rCCL3 treatment (n = 10). (D) AR staining and quantification of BMSCs cultured from aged mice with rCCL3 treatment. Scale bar: 20 μm. (E) Nonphosphorylated (active) β-catenin protein expression when BMSCs undergo osteogenic differentiation with rCCL3 treatment. (F) DKK1 mRNA and protein expression when BMSCs undergo osteogenic differentiation with rCCL3 treatment. (G) DKK1 mRNA and protein expression when BMSCs undergo osteogenic differentiation with rCCL3 treatment. (H) DKK1 protein expression in BMSCs with rCCL3 and/or PD98059 treatment. (I) Active β-catenin activity when BMSCs from young mice undergo osteogenic differentiation with rCCL3 and/or neu anti-DKK1 treatment (n = 10). (J) AR staining and quantification of BMSCs cultured from young mice when undergoing osteogenic differentiation with rCCL3 and/or neu anti-DKK1 treatment. (K) mRNA expression of Runx2, Opn, Bsp, and Ocn when BMSCs from young mice undergoing osteogenic differentiation with rCCL3 and/or neu anti-DKK1 treatment (n = 10). (L) Active β-catenin activity when BMSCs from aged mice undergo osteogenic differentiation with rCCL3 and/or neu anti-DKK1 treatment (n = 10). (M) AR staining and quantification of BMSCs cultured from aged mice when undergoing osteogenic differentiation with rCCL3 and/or neu anti-DKK1 treatment. (N) mRNA expression of Runx2, Opn, Bsp, and Ocn when BMSCs from aged mice undergo osteogenic differentiation with rCCL3 and/or neu anti-DKK1 treatment (n = 10). All data were obtained from 3 independent experiments. Statistics, 2-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar: 40 μm (J and M).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts